I recently celebrated the fifth anniversary of my work as a patient advocate for people diagnosed with amyloidosis in New Zealand. This journey began because of my late husband, Aubrey, who had hereditary ATTR amyloidosis. Out of desperation, we set out to access treatment for him. But without representation…
Sunrise Sunset — Jaime Christmas
Jaime Christmas is a patient advocate and columnist based in Auckland, New Zealand, with her cheeky doggie, Akira. She was a caregiver to a spouse who was afflicted with hATTR amyloidosis. Now she fights for equitable treatment and support for diagnosed patients and their caregivers. Although she now lives without the daily challenges of being a caregiver since her husband’s passing in 2022, she hopes to be still an encourager and listening ear to those presently walking the journey she knows only too well.
Hereditary diseases not only affect the body, but they also ripple through families, shaping relationships, identities, and mental health. I know this reality all too well. My late husband, Aubrey, was diagnosed in 2013 with hereditary ATTR amyloidosis, a genetic disorder caused by mutations in the TTR gene.

I’ve just returned from an amyloidosis conference in Baveno, Italy, organized by the Amyloidosis Alliance. This biennial event — called the International ATTR Amyloidosis Meeting for Patients and Doctors — brings together patients, families, patient advocates, clinicians, and pharmaceutical companies from around the world for two days of…
Advocacy starts with patients and caregivers. It’s the husband who asks the nurse, “Could the lightheadedness mean something more?” It’s the daughter who brings journal articles to her mother’s doctor. It’s the patient who, despite fatigue, shares their story again and again so that the next person might be diagnosed sooner.
In my work as an advocate for the New Zealand Amyloidosis Patients Association (NZAPA), I meet many people with ATTR amyloidosis and their caregivers. I still recall the first diagnosed patient who reached out to me after the charity was established in 2020. We’d just launched NZAPA’s Facebook…
An automated message from LinkedIn recently reminded me that it’s been five years since I started my role as a patient advocate at the New Zealand Amyloidosis Patients Association (NZAPA). I didn’t become an advocate because it was a lifelong ambition, but rather out of necessity. My late husband,…
It’s been nearly a month since the charity I lead, the New Zealand Amyloidosis Patients Association (NZAPA), held a conference for patients and caregivers. The two-day event was made possible by the active participation of those living with various types of amyloidosis, including hereditary ATTR (hATTR), wild-type, and AL…
Here in New Zealand, clinicians and advocates are pushing our country’s government to update its genetic editing and modification legislation. Historically, New Zealand has maintained some of the strictest gene technology regulations globally. Currently, genetic modification is heavily regulated under the Hazardous Substances and New Organisms Act…
Through my roles as a caregiver for my late husband, Aubrey, and as an amyloidosis patient advocate, I’ve been transformed. I once assumed that my life would involve being a wife and stay-at-home mother, with a happy home and a couple of pets to boot. But I became disgruntled…
It’s another stunning summer day here in New Zealand’s Waikato region. We’ve been blessed all week with clear skies and a warm breeze blowing through the house, as the blinds are drawn up and the backyard doors are open. View of the Waikato region in New Zealand. (Photo by Jaime…
December is a month of university graduation here in New Zealand. All the hard work, blood, sweat, and tears conclude in a cacophony of salutations and shouts of joy from family members. Jaime Christmas celebrates with her son Joshua at his college graduation ceremony this month. (Courtesy of Jaime…
According to the Murdoch Children’s Research Institute, there are more than 7,000 rare genetic diseases in the world, mostly affecting children. Additionally, about 300 million people worldwide live with a rare disease, and most of these diseases have no approved treatment. These numbers underscore the urgent need for more research…
Recent Posts
- Heart rhythm problems common in adults with FAP-causing mutation
- The emotional burden of receiving negative genetic test results
- Analysis: RNA-targeted therapies are safe, effective for hATTR-PN
- Hereditary ATTR presents with more severe nerve damage
- Liver transplant, therapies mean longer life with hATTR, data show